Sökning: WFRF:(Egstrup K.)
> Göteborgs universitet >
What resting heart ...
What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF)
-
Gullestad, L. (författare)
-
- Wikstrand, John, 1938 (författare)
- Gothenburg University,Göteborgs universitet,Hjärt-kärlinstitutionen,Wallenberglaboratoriet,Cardiovascular Institute,Wallenberg Laboratory
-
Deedwania, P. (författare)
-
visa fler...
-
- Hjalmarson, Åke, 1937 (författare)
- Gothenburg University,Göteborgs universitet,Hjärt-kärlinstitutionen,Wallenberglaboratoriet,Cardiovascular Institute,Wallenberg Laboratory
-
Egstrup, K. (författare)
-
Elkayam, U. (författare)
-
Gottlieb, S. (författare)
-
Rashkow, A. (författare)
-
Wedel, H. (författare)
-
Bermann, G. (författare)
-
Kjekshus, J. (författare)
-
visa färre...
-
(creator_code:org_t)
- 2005
- 2005
- Engelska.
-
Ingår i: J Am Coll Cardiol. - 0735-1097. ; 45:2, s. 252-9
- Relaterad länk:
-
https://gup.ub.gu.se...
Abstract
Ämnesord
Stäng
- OBJECTIVES: The goal of this study was to explore the question: what resting heart rate (HR) should one aim for when treating patients with heart failure with a beta-blocker? BACKGROUND: The interaction of pretreatment and achieved resting HR with the risk-reducing effect of beta-blocker treatment needs further evaluation. METHODS: Cardiovascular risk and risk reduction were analyzed in five subgroups defined by quintiles (Q) of pretreatment resting HR in the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). RESULTS: Mean baseline HR in the 5 Qs were 71, 76, 81, 87, and 98 beats/min; achieved HR 63, 66, 68, 72, and 75 beats/min; and net change -8, -10, -11, -13, and -14 beats/min, respectively. Baseline HR was related to a number of baseline characteristics. Cardiovascular risk was no different in Q1 to Q4 (placebo groups) but increased in Q5 (HR above 90 beats/min). No relationship was observed between the risk-reducing effect of metoprolol controlled release/extended release (CR/XL) and baseline HR in the five Qs of baseline HR, or achieved HR, or change in HR during follow-up, respectively. CONCLUSIONS: Metoprolol CR/XL significantly reduced mortality and hospitalizations independent of resting baseline HR, achieved HR, and change in HR. Achieved HR and change in HR during follow-up were closely related to baseline HR; therefore, it was not possible to answer the question posed. Instead, one has to apply a very simple rule: aim for the target beta-blocker dose used in clinical trials, and strive for the highest tolerated dose in all patients with heart failure, regardless of baseline and achieved HR.
Nyckelord
- Adrenergic beta-Antagonists/*therapeutic use
- Adult
- Aged
- Aged
- 80 and over
- Chronic Disease
- Delayed-Action Preparations
- Female
- Follow-Up Studies
- Heart Failure
- Congestive/*drug therapy/mortality/*physiopathology
- Heart Rate/*physiology
- Hospitalization
- Humans
- Male
- Metoprolol/*analogs & derivatives/*therapeutic use
- Middle Aged
- Prospective Studies
- Rest/*physiology
- Risk Assessment
- Treatment Outcome
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Gullestad, L.
-
Wikstrand, John, ...
-
Deedwania, P.
-
Hjalmarson, Åke, ...
-
Egstrup, K.
-
Elkayam, U.
-
visa fler...
-
Gottlieb, S.
-
Rashkow, A.
-
Wedel, H.
-
Bermann, G.
-
Kjekshus, J.
-
visa färre...
- Artiklar i publikationen
-
J Am Coll Cardio ...
- Av lärosätet
-
Göteborgs universitet